GeMigliptin Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Gemigliptin is a prolyl-specific dipeptidyl aminopeptidase IV
(DPP IV, DPP-4, CD26) inhibitor approved for the treatment of type
2 diabetes mellitus by the Korean Food and Drug Administration in
2012. Gemigliptin was discovered and developed by LG Life
Sciences and is now the sixth DPP-4 inhibitor approved for the
treatment of type 2 diabetes. At the time this review was prepared,
there were no publications describing the discovery strategy
and preclinical data that led to the advancement of gemigliptin to the clinic.
Verwenden
Gemigliptin Hydrochloride is used in biological studies as a novel dipeptidyl peptidase IV (DPP-IV) inhibitors and potential antidiabetic drug.
GeMigliptin Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte